Personalized medicine (PM) for Parkinson's disease (PD) can range from precision genomic therapies such as ambroxol in glucocerebrosidase mutation-linked PD to treatment tailored for sleep dysfunction in nonmotor subtypes of PD. Additionally, in future pharmacogenetics may also play a part by identification of PD patients susceptible to specific sleep problems such as sudden onset of sleep and facilitate avoiding drugs that may cause these side effects. Age, physical exercise, comorbidities can also drive quality of sleep in PD and form important part of the Parkinson's dashboard-led strand of PM.